Dr. Reddy’s Signs License Deal for Once-Yearly Lenacapavir The Story:Dr. Reddy’s has signed a royalty-free, non-exclusive license agreement with Gilead Sciences for investigational once-yearly lenacap...
Key Highlights: Implications: Dr. Reddy’s launch of Nivorz marks its entry into India’s biosimilar immuno‑oncology segment and adds a lower‑cost checkpoint inhibitor option across 12 appro...
